Actuate Therapeutics develops elraglusib, a GSK-3 inhibitor that targets multiple molecular pathways to slow, stop, or shrink tumors in patients with hard-to-treat cancers. This approach aims to enhance anti-tumor immunity while minimizing adverse effects associated with conventional therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancers are difficult to treat due to their resistance to conventional therapies and the limited number of effective treatment options. These hard-to-treat cancers often involve multiple molecular pathways that promote tumor growth and evade the body's immune response.
Solution
Actuate Therapeutics is developing elraglusib, a novel glycogen synthase kinase-3 (GSK-3) inhibitor, to address the challenges of hard-to-treat cancers. Elraglusib targets multiple molecular pathways involved in tumor growth and resistance to conventional cancer drugs, such as chemotherapy. By inhibiting GSK-3, elraglusib aims to slow, stop, or shrink tumors while minimizing adverse effects. Furthermore, elraglusib is emerging as a mediator of anti-tumor immunity by inhibiting multiple immune checkpoints and regulating immune cell function.
Target Audience
The primary target audience includes patients with hard-to-treat cancers who have limited effective treatment options.
Features
- Novel GSK-3 inhibitor targeting multiple molecular pathways in cancer
- Potential to slow, stop, or shrink tumors
- May enhance anti-tumor immunity through inhibition of immune checkpoints
- Regulation of immune cell function
- Designed to minimize adverse effects compared to conventional therapies